文献速递胸部肿瘤

可切除非小细胞肺癌新辅助卡瑞利珠单抗联合阿帕替尼的疗效、安全性及生物标志物分析:一项2期临床试验

Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
PubMed 文献 · J Thorac Oncol · 2023-03-02

这项2期试验评估了新辅助卡瑞利珠单抗联合阿帕替尼在可切除IIA至IIIB期非小细胞肺癌患者中的疗效与安全性,主要终点为主要病理缓解率。78例患者接受治疗,65例(83%)接受手术,其中37例(57%)达到主要病理缓解,15例(23%)达到病理完全缓解。联合方案显示出有前景的抗肿瘤活性且毒性可控。

要点

  • 65例手术患者主要病理缓解率为57%,病理完全缓解率为23%。
  • 鳞状细胞癌病理缓解优于腺癌(主要病理缓解64%对25%;病理完全缓解28%对0%)。
  • 78例患者中仅4例(5%)发生3级新辅助治疗相关不良事件,无4级或5级事件。

核心结论

  • 新辅助卡瑞利珠单抗联合阿帕替尼在可切除IIA至IIIB期非小细胞肺癌患者中显示出有前景的活性和可控的毒性,可能是新辅助治疗的一种潜在选择。

研究设计与样本

  • 这是一项2期临床试验,纳入组织学确诊的可切除IIA至IIIB期非小细胞肺癌患者(IIIB期仅限T3N2)。
  • 患者接受静脉卡瑞利珠单抗200 mg每2周一次共3个周期,并口服阿帕替尼250 mg每日一次,服药5天休息2天,共6周。
  • 手术计划在停用阿帕替尼后3至4周进行。
  • 主要终点为主要病理缓解率,在至少接受一剂新辅助治疗并接受手术的患者中评估。
  • 2020年11月9日至2022年2月16日期间,78例患者接受治疗,65例(83%)接受手术。

主要发现

  • 65例手术患者均实现R0切除。
  • 65例手术患者中,37例(57%,95%CI:44%-69%)达到主要病理缓解,其中15例(23%,95%CI:14%-35%)达到病理完全缓解。
  • 鳞状细胞癌的病理缓解优于腺癌(主要病理缓解:64%对25%;病理完全缓解:28%对0%)。
  • 影像学客观缓解率为52%(95%CI:40%-65%)。
  • 全部78例入组患者中,37例(47%,95%CI:36%-59%)达到主要病理缓解,其中15例(19%,95%CI:11%-30%)达到病理完全缓解。

临床怎么用

  • 作者认为,新辅助卡瑞利珠单抗联合阿帕替尼在可切除IIA至IIIB期非小细胞肺癌中可能是一种潜在的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Camrelizumab (an anti-programmed cell death protein-1 antibody) combined with apatinib (an antiangiogenic agent) has conferred benefits for advanced NSCLC. We aimed to assess the activity and safety of neoadjuvant camrelizumab plus apatinib in patients with resectable NSCLC. METHODS: In this phase 2 trial, patients with histologically confirmed resectable stages IIA to IIIB NSCLC (stage IIIB, T3N2 only) received intravenous camrelizumab (200 mg) every 2 weeks for three cycles and oral apatinib (250 mg) once daily for 5 days followed by 2 days off for 6 weeks. Surgery was planned 3 to 4 weeks after apatinib discontinuation. The primary end point was major pathologic response (MPR) rate, assessed in patients who received at least one dose of neoadjuvant treatment and underwent surgery. RESULTS: Between November 9, 2020, and February 16, 2022, 78 patients were treated and 65 (83%) underwent surgery. All 65 patients achieved an R0 surgical resection. Among the 65 patients, 37 (57%, 95% confidence interval [CI]: 44%-69%) had an MPR, of whom 15 (23%, 95% CI: 14%-35%) had a pathologic complete response (pCR). Pathologic responses observed in squamous cell NSCLC were superior to adenocarcinoma (MPR: 64% versus 25%; pCR: 28% versus 0%). The radiographic objective response rate was 52% (95% CI: 40%-65%). Among all the 78 enrolled patients, 37 (47%, 95% CI: 36%-59%) had an MPR, of whom 15 (19%, 95% CI: 11%-30%) had a pCR. Four (5%) of 78 patients had grade 3 neoadjuvant treatment-related adverse events. No grade 4 or 5 treatment-related adverse events occurred. Receiver operating characteristic analysis revealed a significant correlation between the maximum reduction of standard uptake values and pathologic response (R = 0.619, p < 0.0001). In addition, baseline programmed death-ligand 1 expression, HOXA9 and SEPT9 methylation levels, and circulating tumor DNA status before surgery were associated with pathologic responses. CONCLUSIONS: Neoadjuvant camrelizumab plus apatinib was found to have promising activity and manageable toxicity in patients with resectable stages IIA to IIIB NSCLC, which might be a potential therapeutic option in neoadjuvant setting.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao J, Zhao L, Guo W, et al. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. J Thorac Oncol. 2023. PMID: 36870519. doi:10.1016/j.jtho.2023.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。